Abstract: Compounds, compositions, and methods for inhibiting pulmonary hypertension are disclosed. The invention is particularly directed to the use of agents that specifically inhibit the activity of certain endogenously produced epoxyeicosatrienoic acids that promote vasoconstriction of pulmonary arteries. These agents are particularly useful for inhibiting hypoxia-induced pulmonary hypertension. The invention further discloses additional compounds, compositions and methods for increasing pulmonary hypertension.

Abstract: An object of the present invention is to develop a new alternative splicing reporter system and to provide a method for detecting alternative splicing patterns in a multicellular organism more precisely, a method for identifying efficiently substances and gene regions that affect alternative splicing in a multicellular organism, and the like by utilizing the alternative splicing reporter system. Specifically, the present invention relates to a method for detecting alternative splicing in a multicellular organism, and a method for identifying substances and gene regions that affect alternative splicing in a multicellular organism, which use a DNA construct in which at least two different reporter genes are inserted into a specific gene that undergoes alternative splicing, or a combination of DNA constructs (a combination of at least two different DNA constructs) in which DNA construct a reporter gene is inserted into a specific gene that undergoes alternative splicing.

Abstract: The invention relates to a method of producing a composition comprising hyperpolarised 13C-pyruvate, the composition and its use as an imaging agent for MR imaging.

Abstract: Provided herein are systems, methods, and compositions for the thermal imaging of cells with nanoparticles.

Abstract: The invention relates to new peptide-based compounds and their use in diagnostic optical imaging techniques. More specifically the invention relates to the use of such peptide-based compounds as targeting vectors that bind to receptors associated with angiogenesis. The compounds are labelled with at least one cyanine dye reporter and may be used as contrast agents in optical imaging in diagnosis of angiogenesis-related diseases.

Abstract: The present invention relates to a mixture of sterile and apyrogenic gases based on CO2 and O2 suitable for producing microbubbles which can be used in the medical, phlebological and diagnostic field. The gas mix allows stable and physiologically acceptable microbubbles to be formed, by means of more standardized procedures which are easy to effect.

Abstract: A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in a time period of less than about 10 minutes. Unit dose devices for storage and delivery of the aminoglycoside antibiotic formulations are also provided.

Abstract: Methods are provided for increasing libido and/or treating erectile dysfunction in a man. The methods include the administration of a formulation testosterone alone, another fast-acting drug to treat erectile dysfunction or a combination of the testosterone and the other drug where at least one is delivered by aersolization. The formulation is preferably aerosolized and inhaled into a patient's lungs where particles of testosterone and/or the fast-acting erectile dysfunction drug deposits on lung tissue and then enter the patient's circulatory system.

Abstract: The invention concerns a blackberry leaf extract and its uses, in particular to slow down skin ageing, to treat the oral and pharyngeal cavity, and there in particular to prevent and slow down periodontitis and the excessive degradation of the periodontal connective tissue as well as damage to the teeth caused by matrix metalloproteinases

Abstract: Compositions that benefit skin and that reduce irritation of the skin are described. The compositions have a skin benefit agent like a hydroxy acid and a vanilloid receptor antagonist. The compositions of this invention can reduce wrinkles on the skin when applied, and they can be formulated to contain glycolic acid and capsazepine.

Abstract: Disclosed is a natural sunscreen composition comprising extracts of Hedychium spicatum and/or Alpinia galanga containing active sunscreen agents, the sunscreen composition devised to protect the skin from the harmful effects of short wavelength UV B rays and long wavelength UV A rays.

Abstract: The invention relates to the use of extended surface aggregates (ESAs) comprising at least one first amphipathic component, which is a basic aggregate-forming component, and at least one second amphipathic component, which decreases aggregate sensitivity to physical stress, including stress created by enforced passage of said ESAs through pores with an average pore diameter at least 50% smaller than the average diameter of the ESAs before said passage, such that the average ESA diameter change induced by such physical stress is reduced by 10% or more, compared to the diameter change induced by such stress in a reference system comprising just the first or just the second aggregate component, in the manufacture of a pharmaceutical preparation for enduring treatment of pathological mammalian skin conditions, including skin irritation, skin inflammation and/or skin damage after topical application, for modifying skin pigmentation and/or for treatment of skin itch.

Abstract: A cosmetic composition comprises, in a cosmetically acceptable medium: at least one coloring agent generating a color by an absorption phenomenon to create a uniform colored background when the composition is applied to a surface, the saturation C* of the composition being 40 or more; a red interference pigment which, when the composition is applied to the surface, can create highlights with a dominant wavelength in the range 580 nm to 650 nm and with an intensity of 3000 cd.m?2 or more.

Abstract: Pulverulent cosmetic formulation comprising at least one hydrophobized silicon dioxide powder, at least one cosmetically relevant constituent and at least 50 wt. % of water, based on the total amount of the formulation, characterized in that the hydrophobized silicon dioxide powder has a tamped density of at least 70 g/l, determined in accordance with DIN EN ISO 787-11.

Abstract: The present invention is drawn to an aqueous composition containing: (a) at least one phospholipid; (b) at least one nonionic surfactant; (c) at least one compound chosen from an alkyl ether carboxylic acid, an alkyl ether carboxylate, a fatty acid having from about 6 to about 40 carbon atoms, and mixtures thereof; and (d) at least one water-insoluble material, and wherein the composition is both homogeneous, and clear to substantially clear in appearance.

Abstract: The present invention is drawn to an aqueous composition containing: (a) at least one fatty monoamine; (b) at least one nonionic surfactant; (c) at least one compound chosen from an alkyl ether carboxylic acid, an alkyl ether carboxylate, a fatty acid having from about 6 to about 40 carbon atoms, and mixtures thereof; and (d) at least one water-insoluble material, and wherein the composition is homogeneous and clear to substantially clear in appearance.

Abstract: The present invention is drawn to an aqueous composition containing: (a) at least one fatty monoamine compound; (b) at least one nonionic surfactant; (c) at least one phosphate ester chosen from alkoxylated alkyl phosphate esters and alkyl phosphate esters; and (d) at least one water-insoluble material, and wherein the composition is both homogeneous, and clear to substantially clear in appearance.

Abstract: The present invention is drawn to a aqueous composition containing: (a) at least one polyamine compound having at least three amino groups; (b) at least one nonionic surfactant; (c) at least one phosphate ester chosen from alkoxylated alkyl phosphate esters and alkyl phosphate esters; and (d) at least one water-insoluble material, and wherein the composition is both homogeneous, and clear to substantially clear in appearance.

Abstract: The present invention is drawn to an aqueous composition containing: (a) at least one fatty quaternary amine; (b) at least one nonionic surfactant; (c) at least one compound chosen from an alkyl ether carboxylic acid, an alkyl ether carboxylate, a fatty acid having from about 6 to about 40 carbon atoms, and mixtures thereof; and (d) at least one water-insoluble material, wherein the composition is both homogeneous and clear to substantially clear in appearance

Abstract: The invention relates to compositions for keratin materials (hair or eyelashes) such as mascaras, topcoats and basecoats containing (a) at least one phosphate surfactant; and (b) at least one polyamide resin.

Abstract: Personal care compositions containing at an alpha-glucan and/or beta-glucan; at least one additional skin and/or hair care active selected from the group consisting of sugar amine, vitamin B3, retinoids, peptides, phytosterol, dialkanoyl hydroxyproline, hexamidine, salicylic acid, n-acyl amino acid compounds, sunscreen actives, water soluble vitamins, oil soluble vitamins, hesperedin, mustard seed extract, glycyrrhizic acid, glycyrrhetinic acid, carnosine, Butylated Hydroxytoluene (BHT) and Butylated Hydroxyanisole (BHA), menthyl anthranilate, cetyl pyridinium chloride, ergothioneine, vanillin or its derivatives, diethylhexyl syrinylidene malonate, melanostatine, sterol esters, tetrahydrocurcumin, their derivatives, their precursors, and combinations thereof; and a dermatologically acceptable carrier.

Abstract: Personal care compositions comprising a dipeptide; one or more of the following: a pentapeptide, a second dipeptide, a vitamin B3 compound, a hexamindine compound, and/or a sugar amine; and a dermatologically acceptable carrier. Methods of using such compositions to treat the condition of keratinous tissue. In certain embodiments, the C terminal amino acid of said dipeptide is threonine.

Abstract: An aqueous structured surfactant composition contains an anionic surfactant selected from isethionate surfactants, taurate surfactants, and sarcosinate surfactants, and mixtures thereof, and an electrolyte and is useful in personal care applications.

Abstract: Embodiments of the present invention are directed to a chemical formulation for de-cuticleizing hair strands comprising boiled water, bleach, shampoo, conditioner, and botanical oil, wherein the shampoo comprises a silicon based composition.

Abstract: This invention relates generally to the field of antimicrobial teat care compositions. More particularly, it relates to a skin-adhering antimicrobial composition comprising a copolymer which contains methacrylic acid and 2-acrylamido-2-methyl-propane sulfonic acid (AMPS) monomeric units, the antimicrobial composition hindering the transfer of bacteria from the environment to underlying teat surfaces and orifices, and which is compatible with both mammalian tissue, including skin, and teat dip compositions.

Abstract: Biocompatible crosslinked polymers, and methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water soluble precursors having electrophilic and nucleophilic groups capable of reacting and crosslinking in situ. Methods for making the resulting biocompatible crosslinked polymers biodegradable or not are provided, as are methods for controlling the rate of degradation. The crosslinking reactions may be carried out in situ on organs or tissues or outside the body. Applications for such biocompatible crosslinked polymers and their precursors include controlled delivery of drugs, prevention of post-operative adhesions, coating of medical devices such as vascular grafts, wound dressings and surgical sealants.

Abstract: Antifouling coating compositions and methods are disclosed, in which the active agent is preferably (?)trans-p-menthane-3,8-diol, (?)-menthol, (?)-menthyl chloride, menthoxypropanediol, (?)-isopulegol or (?)-menthone.

Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising a virus-like particle (VLP) of an RNA-bacteriophage and at least one antigen, wherein the VLP is recombinantly produced in a host, and wherein the amount of host RNA with secondary structure comprised by the VLP is at most 20% of the amount of host RNA with secondary structure originally comprised by the VLP; and wherein the VLP and the at least one antigen are linked with one another. The invention also provides methods for producing the compositions of the invention. The compositions of the invention are useful in the production of vaccines for the treatment of diseases, disorders and conditions. Furthermore, the compositions of the invention are particularly useful to efficiently induce strong antibody responses against the antigen within the indicated context while lowering or eliminating unwanted T cell responses.

Abstract: Compounds having the formula Ia or Ib wherein R1, R2, R3 and R4 are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

Abstract: The present invention provides a compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein the various moieties are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.

Abstract: The invention relates to the use of R-(+)-?-lipoic acid in oxidised or reduced form or derivatives thereof alone or in combination with other effective compounds for the prevention of diabetes.

Abstract: Disclosed is a composition for treating or preventing a viral infection or associated disease comprising a Jab1 protein, a nucleic acid having a nucleotide sequence coding for a Jab1 protein or a recombinant virus expressing a jab1 protein.

Abstract: Antibodies are disclosed herein that bind Spoc cells. In one embodiment the antibodies are monoclonal antibodies. The use of antibodies that bind Spoc cells to identify and/or isolate a sub-population of Spoc cells is also disclosed. In one embodiment, a method for treating a neurologic disorder is provided. The method includes administering a sub-population of Spoc cells and/or and neuronal cells differentiated from Spoc cells to treat a neurologic disorder.

Abstract: A conditionally replicating, aneurovirulent recombinant herpes simplex virus is provided that includes a nucleic acid encoding an expressible chemokine. An expression control element is operably linked to the nucleic acid. A therapeutic composition includes a first conditionally replicating, aneurovirulent recombinant herpes simplex virus having a first nucleic acid encoding a first expressible cytokine operatively linked to an expression control element. A second such herpes simplex virus encoding a second expressible cytokine is also provided with a pharmaceutically acceptable carrier. Preferably, the second cytokine is a chemokine. In a particular embodiment, the first expressible cytokine increases availability of an immunoresponsive cell for activation. The activatable cell is CD4+, CD8+, NK, a dendritic cell, or a combination thereof.

Abstract: The present invention provides a novel bacterial cell composition which comprises cells of Butyrivibrio fibrisolvens having the ability to produce butyric acid, a cultured material thereof or an extract thereof, and a method for inhibiting carcinogenesis, a method for immunostimulating, a method for preventing or treating a pathogen, a method for preventing or treating an inflammatory bowel disease and a method for preventing or treating an allergic disease, which use the same.

Abstract: The present invention provides methods for producing hematopoietic stem cells or vascular endothelial precursor cells, wherein the methods comprise the step of separating PCLP1-positive cells from the hematopoietic tissues of an individual, and then culturing the obtained cells. PCLP1-positive cells obtained from the hematopoietic tissues of an individual can be cultured for a long time, and during culture they produce large quantities of hematopoietic stem cells or vascular endothelial precursor cells. The hematopoietic stem cells or vascular endothelial precursor cells obtainable by the present invention can be utilized for regenerative medicine.

Abstract: The present invention relates broadly to methods for stimulating neural progenitor cell migration to certain regions of the nervous system where the neural progenitor cell naturally would not migrate. These methods have wide interest in fields related to the development of therapeutic approaches for addressing a broad range of neurodegenerative and demyelinating pathologies of the central nervous system. In order to accomplish these various outcomes, the invention provides modalities for introducing into a cell of the CNS a substance that promotes polysialylation of a protein component of the cell. This process underlies various methods of the invention, such as a method of polysialylating a protein of the cell, a method of promoting migration of a neural progenitor cell from a first region of a brain to a second region of the brain, or a method of promoting a neural progenitor cell originating in a first region of a brain to differentiate in a second region of the brain.

Abstract: A cellular scaffold that is suitable for tissue regeneration, cell culture and in vitro assays. The invention relates to a layered cell scaffold that is seeded with mesenchymal and ectodermal cells. The layered cellular scaffold comprises an inoculum of mesenchymal cells and ectodermal cells positioned between two opposing scaffolds in a sandwich configuration. The layered cell scaffold provides a functional skin equivalent that is suitable for transplantation and in vitro cell-based assays.

Abstract: Methods of treating autoimmune diseases, allergic responses, cancer, inflammatory diseases, or fibrosis in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.

Abstract: The present invention relates to a treatment of a leukodystrophy by administration of an adipose-derived stem cell. Specifically, the present invention relates to the treatment of Krabbe disease with an adipose derived stem cell differentiated to express galactocerebrosidase.

Abstract: The present invention relates, in general, to atherosclerosis and, in particular, to a method of treating atherosclerosis and to cells suitable for use in such a method.

Abstract: The invention involves a method for extending the shelf life of a powdered nutritional formulation that contains LGG by reducing and maintaining a threshold water activity or moisture content in the powdered LGG-containing formulation.

Abstract: Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are disclosed. TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.

Abstract: An ophthalmic composition that includes an epithelium cell stabilizer component. The epithelium cell stabilizer component may be one or more of diglycine, triglycine, tetraglycine, pentaglycine. The invention is also directed to a method of treating or preventing dry eye comprising administering an effective amount of the ophthalmic composition to the eye.

Abstract: The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.

Abstract: The present invention relates to compositions comprising lysostaphin variants and methods of using the same. In particular, the present invention provides de-immunized lysostaphin variants and methods of using the same (e.g., to treat microbial infection in or on a subject).

Abstract: The field of invention relates to Vitamin C compositions, and in particular to Vitamin C compositions containing ascorbate-glucose transport enhancers. In at least one aspect, a composition is provided herein that includes ascorbate in an amount from about 0.1% by weight of actives to about 99.9% by weight of actives, and at least one ascorbate-glucose transport enhancer in an amount from about 0.01% by weight of actives to about 99.0% by weight of actives. In another aspect, a method of improving the transport of ascorbate into cells and tissues is provided that includes providing a composition comprising ascorbate and at least one ascorbate-glucose transport enhancer.

Abstract: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.

Abstract: Contemplated compositions and methods are directed to the use of a proteinase to reduce capsaicin-induced pain sensation in a mammal. Preferably, the proteinase comprises a bromelain preparation in a liquid formulation for topical or enteral administration. In additional aspects of the inventive subject matter, a proteinase inhibitor is present in pepper spray to avoid inactivation of capsaicin by a proteinase.

Abstract: A method is provided for the localized intravascular administration of a fibrinolytic metalloproteinase to a human subject in amounts that are both safe and effective to lyse an occluding fibrin-containing blood clot, while also avoiding the neutralizing effects of ?2-macroglobulin in the circulating blood. A method is also provided for the treatment of a blood clot in, around or attached to an indwelling vascular access device. A method for restoring patency and function of an indwelling vascular access device is also provided.